Novartis

Novartis to cut up to 130 Basel jobs in biologics restructuring

Novartis plans to cut up to 130 jobs in Basel by the end of 2027 as it ends small-scale biologics production at its Kleinbasel site. Some activities will move to the company’s campus across the Rhine, highlighting continuing restructuring in Swiss pharmaceuticals.